Teva Inks $100m+ Deal To Settle West Virginia Opioid Claims
Israeli Company ‘Continues To Actively Negotiate A National Settlement’
Executive Summary
Teva has struck a further cash-and-medicines settlement agreement to resolve opioid-related claims in the US. A bench trial had been due to start in West Virginia by the end of this month, where Teva is to pay $75m over 15 years plus generic Narcan.
You may also be interested in...
Teva Inks $4.35bn Nationwide US Opioids Settlement Agreement
Teva is to put more than $3bn in cash on the table over the next 13 years to resolve longstanding opioid-related claims against the company in the US.
Teva Settles With San Francisco But New York Could Be Set To Prize Open Old Wounds
Teva has settled the final outstanding advanced US state-level opioid-related case against the firm, but recent allegations from the New York attorney general could see the firm back in court sooner rather than later.
What’s Next? Five Things To Look Out For In July
This month, long-awaited new pricing measures in Canada will come into force, while several trials will either kick off or end, including a liability opioids case involving Teva in San Francisco and Hatch-Waxman litigation over Otsuka/Lundbeck’s Rexulti.